{
    "id": 4007,
    "name": "bladder carcinoma",
    "source": "DOID",
    "definition": "A urinary bladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. [url:https\\://www.mayoclinic.org/diseases-conditions/bladder-cancer/symptoms-causes/syc-20356104]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4007",
    "evidence": [
        {
            "id": 717,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "A retrospective study of a Phase II trial correlated increased sensitivity to the mTOR inhibitor Afinitor (everolimus) with TSC1 mutations in bladder cancer patients, including one patient harboring TSC1 E636fs* who had a durable complete response (PMID: 22923433).",
            "molecularProfile": {
                "id": 1002,
                "profileName": "TSC1 E636fs"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 431,
                    "pubMedId": 22923433,
                    "title": "Genome sequencing identifies a basis for everolimus sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22923433"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1035,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).",
            "molecularProfile": {
                "id": 544,
                "profileName": "FGFR3 wild-type"
            },
            "therapy": {
                "id": 1465,
                "therapyName": "R3Mab",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 742,
                    "pubMedId": 19381019,
                    "title": "Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19381019"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1036,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R3Mab decreased dimer formation and constitutive activation of FGFR3 S249C, and inhibited growth of bladder cancer cell lines harboring FGFR3 S249C in culture and in xenograft models (PMID: 19381019).",
            "molecularProfile": {
                "id": 1736,
                "profileName": "FGFR3 S249C"
            },
            "therapy": {
                "id": 1465,
                "therapyName": "R3Mab",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 742,
                    "pubMedId": 19381019,
                    "title": "Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19381019"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1247,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "A retrospective study of a Phase II trial correlated increased sensitivity to the mTOR inhibitor Afinitor (everolimus) with TSC1 mutations in bladder cancer patients (PMID: 22923433).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 431,
                    "pubMedId": 22923433,
                    "title": "Genome sequencing identifies a basis for everolimus sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22923433"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2466,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human bladder cancer cell line over expressing EHMT2 was sensitive to BIX-01294 as demonstrated by suppression of cell growth (PMID: 21847359).",
            "molecularProfile": {
                "id": 8035,
                "profileName": "EHMT2 over exp"
            },
            "therapy": {
                "id": 2862,
                "therapyName": "BIX-01294",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3123,
                    "pubMedId": 21847359,
                    "title": "Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21847359"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3830,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).",
            "molecularProfile": {
                "id": 16525,
                "profileName": "AKT1 E17K NRAS Q61R"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2275,
                    "pubMedId": null,
                    "title": "Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/3685"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3912,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR-42 synergized with cisplatin to induce apoptosis of bladder cancer cells in xenograft models (PMID: 25748177).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3400,
                "therapyName": "AR-42 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4290,
                    "pubMedId": 25748177,
                    "title": "Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25748177"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9606,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Adriamycin (doxirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202).",
            "molecularProfile": {
                "id": 26918,
                "profileName": "MST1R dec exp"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7317,
                    "pubMedId": 26772202,
                    "title": "RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26772202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9607,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Ellence (epirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202).",
            "molecularProfile": {
                "id": 26918,
                "profileName": "MST1R dec exp"
            },
            "therapy": {
                "id": 1013,
                "therapyName": "Epirubicin",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7317,
                    "pubMedId": 26772202,
                    "title": "RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26772202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9780,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bladder carcinoma cells expressing HRAS Q61L demonstrated sensitivity to NS1, resulting in inhibition of Mapk signaling and cell proliferation in culture (PMID: 27820802).",
            "molecularProfile": {
                "id": 3563,
                "profileName": "HRAS Q61L"
            },
            "therapy": {
                "id": 5228,
                "therapyName": "NS1",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7600,
                    "pubMedId": 27820802,
                    "title": "Inhibition of RAS function through targeting an allosteric regulatory site.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27820802"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12332,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type urinary bladder carcinoma (PMID: 28765324).",
            "molecularProfile": {
                "id": 587,
                "profileName": "MET wild-type"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18460,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEN1309 reduced tumor volume in a cell line xenograft model of LY75-positive bladder carcinoma and in patient-derived xenograft (PDX) models with heterogeneous LY75 expression (PMID: 31227646).",
            "molecularProfile": {
                "id": 33235,
                "profileName": "LY75 positive"
            },
            "therapy": {
                "id": 8717,
                "therapyName": "MEN1309",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16207,
                    "pubMedId": 31227646,
                    "title": "MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227646"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00942331",
            "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1295,
                    "therapyName": "Bevacizumab + Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01259063",
            "title": "RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2279,
                    "therapyName": "Everolimus + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01366144",
            "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01391143",
            "title": "Safety Study of MGA271 in Refractory Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2863,
                    "therapyName": "MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01438112",
            "title": "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer",
            "phase": null,
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2524,
                    "therapyName": "Gemcitabine + interferon gamma + Mitomycin C + Valrubicin",
                    "synonyms": null
                },
                {
                    "id": 2523,
                    "therapyName": "CG0070",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01688999",
            "title": "Cabozantinib for Advanced Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01938573",
            "title": "Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2289,
                    "therapyName": "Cisplatin + Gemcitabine + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02169284",
            "title": "Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02432963",
            "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5547,
                    "therapyName": "MVAp53 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02444793",
            "title": "A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6332,
                    "therapyName": "Mogamulizumab + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02636036",
            "title": "Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3620,
                    "therapyName": "Enadenotucirev + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02723955",
            "title": "Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4409,
                    "therapyName": "GSK3359609",
                    "synonyms": null
                },
                {
                    "id": 4410,
                    "therapyName": "GSK3359609 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03171025",
            "title": "Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319745",
            "title": "A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03430895",
            "title": "Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03693014",
            "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT04054752",
            "title": "Vaccine Response With NT-I7",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9320,
                    "therapyName": "NT-I7",
                    "synonyms": null
                }
            ]
        }
    ]
}